WHO SEARO and George Institute Sign Two-Year AI Digital Health Pact for South-East Asia NCDs

A two-year collaboration between WHO South-East Asia Regional Office (SEARO) and the George Institute for Global Health signals a shift in how real-world evidence and AI-driven tools may be evaluated within the region's regulatory frameworks for non-communicable diseases. For regulatory affairs leads and pharmacovigilance teams operating across South-East Asian markets, the partnership introduces a WHO-backed reference point that could inform future digital health submission standards.

The collaboration is structured around three operational pillars: strengthening primary healthcare systems, generating real-world evidence from NCD programmes, and supporting responsible AI adoption across member states. The real-world evidence component carries particular weight for QA and regulatory functions, as data standards developed under this initiative could be referenced in future ICH E8(R1)-aligned study designs or regional pharmacovigilance guidance.

The George Institute brings an established research infrastructure in low- and middle-income settings across the region, while WHO SEARO provides the normative authority to translate findings into policy recommendations. That combination positions outputs from this collaboration, evidence frameworks, AI governance principles, data interoperability standards, as likely inputs to national regulatory agency guidance rather than purely academic deliverables.

For manufacturers with digital therapeutics, AI-assisted diagnostics, or connected device submissions pending in South-East Asian markets, the trajectory is relevant: regulatory expectations in these jurisdictions have historically aligned with WHO guidance documents, and a two-year evidence-generation programme of this scope could accelerate the formalisation of submission requirements for AI-enabled health technologies.

The pharmacovigilance dimension is equally consequential. Real-world evidence generated through primary care networks across the region could establish baseline data quality benchmarks that national regulators adopt when assessing post-market surveillance submissions for NCD-indicated products.

The partnership's two-year timeline places its primary outputs in 2027 and 2028, a window that overlaps with several national digital health regulatory reviews already underway across WHO SEARO member states.

Source: Media4Growth via Indian Pharma Post, 12 June 2026.